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Abstract
A shift in the culture and practice of health and development research is required to maximise the real-world use
of evidence by non-academic or non-research-oriented audiences. Many frameworks have been developed to
guide and measure the research utilisation process, yet none have been widely applied. Some frameworks are
simplified to an unrealistic linear representation while others are rendered overly complex and unusable in an
attempt to capture all aspects of the research utilisation process. Additionally, many research utilisation frameworks
have focused on the policy development process or within a clinical setting, with less application of the translation
process at the programme level. In response to this gap – and drawing from over a decade of experience
implementing research utilisation strategies – we developed a simple, four-phase framework to guide global health
and development efforts that seek to apply evidence to policies and programmes. We present a detailed
description of each phase in our framework, with examples of its relevance and application illustrated through our
own case study experiences in global health. We believe the utility of this framework extends beyond the health
sector and is relevant for maximising use of evidence to achieve the Sustainable Development Goals.
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Background
In 2004, WHO published the World Report on Know-
ledge for Better Health [1], emphasising the need for
greater investments in translating knowledge into action
to more quickly foster country-level evidence-informed
policies and for implementation and scale-up of proven
life-saving interventions. While general agreement exists
that these improvements are needed, researchers and
policy-makers have identified many barriers and chal-
lenges that inhibit the research utilisation process [1–5].
A shift in the culture and practice of health and develop-
ment research is required to maximise the real-world
use of evidence by non-academic or non-research
oriented audiences. Despite the many calls for greater
action to bridge the ‘know–do gap’ or to develop
evidence-informed policies, affecting change in the
culture and practice of research is slow and requires de-
liberately managed and sustained efforts [1, 6, 7].
In response to the know–do gap, publications on the
conceptualisation of research utilisation (RU) – a term
that is often used interchangeably with knowledge
translation, research uptake or evidence-informed policy
– have increased, and included identification of barriers
and facilitators to use as well as strategies to improve re-
search uptake [2, 3, 5, 8]. Consequently, many frame-
works have been developed to guide and measure the
RU process, but few have been widely applied, in part
because the dynamic processes and actors involved are
diverse and context-specific, but also because some
frameworks provide limited ‘how-to’ support for imple-
mentation [9–11]. Some frameworks represent RU
within a linear process [12], while others present a more
complex RU process, capturing the dynamic relation-
ships between research producers, end users of research,
and ‘intermediaries’ [9, 10, 12] to target the best RU
output balancing end users’ ‘knowledge need’ and
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appropriate ‘evidence response’ [13]. Despite their at-
tempts to represent the dynamic nature of RU, many of
the existing RU frameworks have been criticised as inad-
equate due to their lack of direct links between research
and its use [4] or because of their inapplicability to low-
and middle-income country (LMIC) contexts and
cultures [4, 8, 10]. A scoping review of knowledge bro-
kering found that guiding conceptual frameworks and
models varied, focused on linkage and exchange, and
depended on multiple frameworks for guidance, yet
strong evidence for effective knowledge brokering
approaches were limited [14]. Another recent scoping
review of integrated knowledge translation strategies
found that there is a lack of explicit description of
underlying logic or use of frameworks for associated
strategies or approaches implemented for increasing re-
search uptake [15].
Additionally, published RU frameworks have focused
largely on the policy development process or within a
clinical setting, with less application of the translation
process at the programme level [5, 16–19]. The applica-
tion of evidence at the programme level is particularly
salient for supporting the replication, scale-up and insti-
tutionalisation of evidence-based programmes and
practices within a country. While the impact of evidence-
based programming has been demonstrated through
research, descriptions of specific strategies to translate and
adapt evidence-based programmes to other contexts
remains sparse, particularly in LMICs [1, 4, 6, 8].
In response to the need for a RU framework driven by
both policy and programme needs, inclusive of specific
RU strategies and applicable to LMICs, we developed a
simple, four-phase framework that builds on the current
RU literature and reflects over a decade of experience
implementing RU strategies to improve global health
policy and practice.
A RU framework
Figure 1 shows the FHI 3601 RU framework, which con-
sists of four phases, namely foundation, research, trans-
lation and institutionalisation. Three key types of actors
– evidence producers, knowledge brokers and end users
of evidence – are essential to the progress and flow of
each phase and, though these groups are categorised dis-
tinctly, they often overlap and are not mutually exclu-
sive. Two crucial decision points for translation and
adoption are identified at the end of the research phase
and during the translation phase, respectively [20]. The
circular representation of the model demonstrates the
dynamic nature of the process; actors may stop at any
point along the continuum and return to a prior phase.
Furthermore, experience demonstrates that activities in
different phases may be implemented concurrently,
overlapping, or back and forth. This dynamic process al-
lows for constant learning and evaluation within and be-
tween phases. The circular representation also captures
the importance of policy, programmes and practice feed-
ing back into research. The framework was inspired by,
Fig. 1 FHI 360 Research Utilisation Framework
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and adapted in part, from two existing frameworks by
Wilson et al. [16] and El Jardali et al. [20], both of which
built on existing knowledge translation theories and
models. As a long standing RU programme in global
health, we often referred to the Wilson et al. framework
[16], although we found it to have similar limitations as
reported above. A product of the Centers for Disease
Control and Prevention (CDC), the framework empha-
sised clinical evidence, did not identify key actors, and
did not have a foundational phase. The El Jardali et al.
[20] framework was referred to for its policy application,
yet remained limited for our programmatic needs, as
there was less emphasis on programme implementation
compared to policy implementation. The combination of
some key concepts of these frameworks, in addition to
our own experiences in the field, led us to develop a
simplified framework to inform programmes and pol-
icies in LMICs. The simplicity of the framework is
important from a programmatic perspective as it em-
phasises key areas within a very complicated process,
making it more digestible for a broader audience.
Central to our framework is the engagement and
interaction of key actors essential to the RU process.
This human element distinguishes the framework
from others as it drives the context and climate for
RU – the relationships, capabilities, politics and
demand for evidence – that determine the success of evi-
dence uptake. In order to keep the framework simple, we
have excluded some elements that we felt were already ob-
vious such as larger contextual factors. While many exter-
nal factors may dictate the success or failure of research
and evidence uptake, such as capacity or political climate,
they are not visually captured.
We present a description of each phase in our framework
and provide examples of its relevance and application
within global health research, policy and programming. Al-
though we focus on our experiences in global health, we
believe the utility of this framework extends beyond the
health sector and is relevant for concerted action to achieve
the Sustainable Development Goals.
Key actors in RU
The three categories of key actors represented in the
framework are evidence producers, knowledge brokers
and end users of evidence. These key actors have differ-
ing roles and commitments throughout each of the
phases. Individual evidence producers and knowledge
brokers are typically from academic institutions and re-
search or policy institutes such as think tanks, or are
employed within research units of governmental or non-
governmental organisations. Organisations and institu-
tions may also be considered evidence producers and
knowledge brokers, in addition to individuals. Evidence
producers, as the name suggests, are those who lead the
design and execution of research or data collection ac-
tivities. Knowledge brokers are considered intermediar-
ies to help communicate evidence and facilitate evidence
use between producers and end users [14]. End users are
those expected to apply evidence to programmes or pol-
icies and can range from policy-makers to advocates,
programme implementers, members of the media and
civil society organisations.
The capacity of individuals or institutions to perform
these three key roles within a country may differ. For in-
stance, the capacity of local evidence producers to sup-
ply high-quality research and data may be limited in
some countries as compared to others; this is often the
case in LMICs, though many donors have been directing
resources for years toward building local research cap-
acity [21, 22]. Additionally, capacity to use and apply evi-
dence among end users may be a constraint to achieving
evidence-based policies and programmes in some coun-
tries despite donor-funded projects that have also fo-
cused on building capacity of end-users to seek out,
understand and apply evidence [23]. Even when capacity
exists in a country both to produce and to apply evi-
dence, research uptake is not always achieved because
evidence-producers and end-users are not linked to each
other [24]. Furthermore, the use of evidence can be of a
political nature as it is linked to the human element and
how people make decisions based on relationships and
political dynamics. Thus, knowledge brokers are the im-
portant third category to help bridge the gap between
producers and end users.
Foundation phase
The foundation phase emphasises the engagement of
various stakeholders to understand the most pressing
knowledge needs and to set research priorities. Stake-
holders who are involved in research priority-setting
may include policy-makers, civil society representatives,
researchers, donors, health providers, private sector rep-
resentatives, advocates, implementing partner organisa-
tions and individual citizens. The primary aim of
research priority-setting is “to gain consensus about
areas where increased research effort including collabor-
ation, coordination, and investment will have wide bene-
fits to society” [25]. The foundation phase guides the
overall process and is instrumental to establishing on-
going relationships and collaborations throughout the
rest of the phases. In practice, stakeholder engagement
occurs at all points in the framework and throughout a
study, but may not be initiated from the beginning of a
study. However, the framework emphasises that, ideally,
engagement activities should happen at the start, build-
ing on experiences of successful evidence uptake that is
often based on the strength of relationships and engage-
ment with key stakeholders.
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Research priority-setting is particularly important in
contexts with limited financial and human resources as
it is essential to maximise the impact of research invest-
ments [26]. However, approaches for engaging diverse
stakeholder groups in evidence-based research priority-
setting in LMICs have not been evaluated or docu-
mented well. Nonetheless, the value and function of
research priority-setting is well-recognised and instru-
mental in strengthening country-level research capacities
overall, a process that lays the foundation for greater use
of investments in conducting needed research and ap-
plying findings [1, 27]. Research priority-setting can be a
complex activity; a checklist outlining nine common
themes of good practice for research priority-setting was
developed by Viergever et al. [26] to assist priority-
setting processes by countries.
Priority-setting at the country level should be country-
led and feed into national strategies and implementation
plans. Specific activities related to research priority-
setting can include open fora, town hall meetings, con-
ferences, targeted consultations or workshops. These
activities allow different stakeholder groups to interact
and identify synergies for achieving shared goals and ob-
jectives, within or across sectors.
Research phase
The research phase consists of study conceptualisation
and implementation, including protocol development,
data collection, and data analysis and interpretation.
While researchers are the main actors during implemen-
tation and analysis within our framework, all key actors
– evidence producers, knowledge brokers and end users
– take part in study conceptualisation to ensure its rele-
vance, which maximises eventual uptake of the findings.
FHI 360 developed a RU planning tool, most often ap-
plied by the RU expert playing the knowledge broker
role, as a guide to consider determinants of eventual up-
take and to make decisions regarding research design,
stakeholder engagement and communication strategies,
and dissemination approaches. For instance, a key rec-
ommendation for intervention studies or pilot feasibility
projects is to design the intervention as part of the exist-
ing system, rather than rolling out a highly complex and
managed model, in order to increase the likelihood that
it can be scaled up [28]. Another recommendation is to
document the implementation process for the interven-
tion in order to identify best practices and avoid pitfalls
for future replication [29]. We have developed and used
an intervention tracking tool to help document the im-
plementation process. The tool aims to pinpoint when
and how the intervention differed from the original de-
sign, identify activities which are not always included in
final research reports and, most importantly, articulate
what is needed for scale-up if the pilot is successful.
Engagement of stakeholders throughout the research
phase, not only during conceptualisation but also during
the development of a research utilisation plan, data ana-
lysis and interpretation, and results synthesis, supports
greater participation during dissemination and uptake of
recommendations [28]. Stakeholder analysis can be used
to help identify key stakeholders and how to critically
engage them throughout the RU framework phases. Sev-
eral tools exist to facilitate stakeholder identification and
analysis, including one that we developed as part of our
package of RU tools.2
At the end of the research phase, the framework notes
a critical decision point – the decision to translate. The
decision to translate is the active decision to develop
and disseminate knowledge products based on research
findings to drive thoughtful discussion and widespread
use of the evidenced-based programme, practice or pol-
icy [20]. Ideally, this is a collective decision taken by all
three categories of key actors and helps bridge the re-
search to translation phases. Importantly, we character-
ise this as a ‘decision point’ because uptake of even high
quality, compelling evidence is not automatic and re-
quires deliberate action. While the framework includes a
research phase, non-research field practitioners may find
the framework applicable at this decision point – to
move an existing body of evidence or programme prac-
tice to inform policy and other practice.
Translation phase
The translation phase actualises the first decision to start
turning evidence into actionable products for wide dis-
semination and use. Through its three sub-phases and a
decision point, knowledge products are created, dissem-
ination and advocacy activities are conducted to pro-
mote wide adoption of the evidence, and uptake of
evidence-based practices or research results is actively
supported. This phase is the longest in the framework,
signifying that it often takes time to achieve uptake and
transition to true institutionalisation.
According to the framework, evidence producers and
knowledge brokers work together to develop knowledge
products that effectively synthesise evidence and facili-
tate its application to programmes and policies. Know-
ledge products may include evidence briefs, technical
guidelines, programme and intervention guidance, and
job aids. Studies with decision-makers have shown that
key messages, or take-home messages, that are solution-
oriented and in short form, such as evidence briefs, are
more effective than a research report [30]. Targeted mes-
sages to the audience of interest are also important for
an effective knowledge-transfer strategy. Thus, multiple
audience-specific messages should be generated – for
decision-makers as well as programme users – in a
way that adapts to the language of the intended users
Kim et al. Health Research Policy and Systems  (2018) 16:9 Page 4 of 10
[31–33]. Users of research who are intended to imple-
ment the new policy or programme require additional
products, such as technical guidelines and job aids,
which can help to ensure that practitioners are chan-
ging behaviour and routinely applying evidence-based
practices in their jobs. Audiences intended to use job
aids or other knowledge products should be engaged
in their development and field-testing [28, 34].
A dissemination strategy for spreading research results
or evidence-based practices to target audiences through
the most effective channels [28, 35], which was devel-
oped as part of the research utilisation plan during the
research phase, is also implemented during this phase.
Evidence-based knowledge products can be disseminated
through forums, policy dialogues, national and inter-
national conferences, advocacy campaigns and media
engagement. While the mechanism and forum for dis-
semination is important, the voice carrying the message
is equally as important as the messages themselves.
Identifying and engaging champions or an opinion
leader to take an active role in dissemination activities
can increase the likelihood for uptake of an evidence-
based practice or programme [35, 36]. The target audi-
ences identified in the dissemination plan will inform
what messages and avenues for dissemination are most
effective and strategic for the greatest uptake.
The decision to adopt the evidence-based programme,
practice or policy is the second critical decision point
along the framework and is made by end users, including
communities, programme managers, implementing orga-
nisations or policy-makers [20]. End users may require
additional evidence or have other questions that require
investigation resulting in a feedback loop to the research
phase before the decision to adopt can be made.
Once end users have decided to adopt a piece of evi-
dence into policy and/or programmes, it must be applied
in real-life scenarios. To do so, evidence-producers and
knowledge brokers may provide technical assistance to
end-users to conduct study tours to see application of
the evidence at scale, revise or update policies or norms,
develop monitoring and improvement plans, and/or
build technical capacity for implementation. Adoption
and replication of an effective intervention or practice
often requires the proper policies and guidelines that are
relevant to the local context to be in place, testing and
refining of the core programme elements, and training
practitioners to implement appropriately, with ongoing
assistance and capacity-building [29, 37, 38]. Documen-
tation, monitoring and evaluation of these processes, in-
cluding client-level outcomes, as well as identifying
which populations benefit more or less, are essential to
building more evidence for the practice in other con-
texts. Often, programmes are introduced without readily
assessing the environment for adequate policies or
readiness for introduction of new interventions. A more
strategic approach to uptake and practice should lead to
more sustainable programming in the future.
It is important to note that a given RU effort may
jump between or move concurrently through the sub-
components of the Translation phase, or between and
through the Translation and Institutionalisation phases,
as happened in our case study of community-based fam-
ily planning (CBFP) in Zambia described below.
Institutionalisation phase
Institutionalisation of evidence-based programmes,
practices and policies is the main outcome of the evi-
dence translation process. The institutionalisation
phase is where evidence use is established as an or-
ganisational norm and proven interventions are main-
tained, funded and scaled-up [20]. Sustainability of
health and development programmes is determined
by a range of factors, including the availability of hu-
man and financial resources, integration into larger
systems and institutions, and ongoing political will
and support, and requires continuous and systematic
efforts over long periods of time in order to ensure
that evidence is truly institutionalised [39].
Identifying sustainable human resources and finan-
cing mechanisms are the biggest challenges in the
institutionalisation of promising and innovative solu-
tions in low-income countries. While low-income
countries take on over 50% of the global disease bur-
den, they account for less than 2% of global public
health spending [40]. Efforts to create a more coordi-
nated global architecture for development targets and
financing have been made through the Millennium
Development Goals and its follow-on Sustainable De-
velopment Goals. Successfully achieving these goals
will require greater coordination and alignment by
country stakeholders and international partners [41]
to agree upon evidence-based interventions as well as
the strategies and resources to implement and scale
them. Though not always the case, in our experience
that we present from Zambia, consistent donor-
support (in this case, from the United States Agency
for International Development (USAID)) aligned to
global consensus for a particular practice (WHO
endorsement of community-based provision of inject-
ables) helped local stakeholders move from introduc-
tion to institutionalisation. Sustainable financing and
human resources ensure that evidence-based pro-
grammes and services are not disrupted and can
therefore result in greater development and health
impacts. The availability of well-trained human re-
sources from field implementers to policy-makers sets
the stage for institutionalisation through systematic
changes in norms and practices.
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Zambia case study
Background
Herein, we will describe a RU framework experience
from a demonstration project of a CBFP programme in
which depot-medroxyprogesterone acetate (DMPA) was
added to the family planning (FP) methods already being
provided by community-based distributors (CBD) in
Zambia [42]. In Zambia, an inequitable distribution of
FP service use exists among rural women compared to
urban women due to traditional misconceptions and
myths, long distances to health facilities, frequent stock-
outs of contraceptives at both health facility and
community levels, and inadequately trained personnel
resulting in long queues at health facilities. CBDs have
historically played an important role in providing CBFP
services to women in rural areas, though their impact is
often limited by providing only condoms and oral
contraceptive pills. Delivery of DMPA, one of the most
popular methods among women of reproductive age, by
CBDs, would help expand the reach of FP services and
meet the reproductive health needs of women in rural
areas. Studies in other countries found this delivery ap-
proach to be safe and effective. The pilot study in
Zambia aimed to examine the incremental or additive
effect of CBDs providing DMPA, including (1) their abil-
ity to provide DMPA to clients safely and effectively; (2)
the acceptability of, and client satisfaction with, CBD
agent delivery of DMPA; (3) if and how the workload of
CBD agents and their supervisors changed with the
addition of CBD provision of DMPA; and (4) the add-
itional cost per couple-years of protection of adding
DMPA to the existing CBD-delivered FP programme.
The study was implemented by FHI 360 and ChildFund
Zambia, in coordination with the Zambia Ministry of
Health (MOH) and with support from the USAID.
Key actors in the pilot study
There were several key actors involved in the CBFP
demonstration project in Zambia. End users were com-
prised of the Government of Zambia MOH officials,
health workers and associations of health professionals,
and non-governmental organisations implementing
community health programmes in the country. Evidence
producers were researchers at FHI 360, who led the re-
search and supported implementation of the programme
by Childfund Zambia. ChildFund staff were both evi-
dence producers, as they were deeply involved in study
design and data interpretation, and end users since, as
they were able to incorporate findings into future
programme implementation. Knowledge brokers in-
cluded RU experts within FHI 360 who partnered with
researchers and worked closely with implementers and
end users throughout and after the study. The building,
re-building and strengthening of relationships among
key actors was instrumental in the institutionalisation of
the programme, particularly as unforeseen changes in
the government structures and policy-level stakeholders
occurred during the process.
Foundation phase: growing demand for a CBFP research
agenda
The 2006–2010 National Health Strategic Plan of
Zambia identified “strengthen family planning and
contraceptive choice programmes, with a special focus on
rural districts” [43] as a key strategy for decreasing ma-
ternal mortality and increasing access to integrated re-
productive health. Globally, WHO began advocating for
increased task sharing of some health services to lower
cadres in order to rapidly increase healthcare access
needs and address human resource crises in under-
served areas [44, 45]. In 2008, discussions in Zambia
began regarding the inclusion of DMPA into the CBD
programme and, by 2009, the MOH requested that
pilot research be conducted on the delivery of DMPA
by CBD agents.
Research phase: implementation of the pilot study
With approval from the Government of Zambia, FHI 360
and ChildFund convened an initial stakeholder meeting to
discuss the design of the pilot study to add injectable
contraception to ChildFund’s CBFP programme. Govern-
ment officials and national stakeholders requested mea-
sures of programme impact to be included, in addition to
local confirmation of the safety, feasibility and acceptabil-
ity of CBD agent provision of injectable contraception.
From November 2009 to February 2011, a RU expert, act-
ing as knowledge broker, supported the study during this
phase, managing stakeholder engagement, contributing to
study design, tracking cost information and documenting
implementation details using the intervention tracking
tool. Preliminary findings were presented to a small group
of stakeholders in May 2011. At this meeting, a ‘decision
to translate’ effectively occurred when the FP Tech-
nical Working Group made several recommendations
to the MOH based on the preliminary findings. These
included to continue provision of DMPA by CBD
agents in pilot districts, develop a phased national
scale-up plan, and revise policy to permit CBD agents
to administer DMPA. During this time, a high level
well-respected champion was brought on board to
present at the meeting and help implement recom-
mendations, greatly facilitating the transition to the
translation phase.
Translation and institutionalisation: a winding path to
wide-spread and government-supported CBD of DMPA
In this case study, activities overlapped between the
Translation and Institutionalisation phases, with
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considerable movement between the two (Fig. 2). Fol-
lowing the dissemination of preliminary findings, a
larger dissemination meeting with more stakeholders
was held in October 2011 to present the full pilot
study results. Knowledge products included a Road
Map for National Scale-Up of the programme which
had been drafted based on the preliminary findings.
At the October meeting, members of the General
Nursing Council and the Health Professionals Coun-
cil of Zambia were vocal about their concerns with
lower level cadres administering injections. It was
thus recommended that the MOH engage with these
professional bodies to clarify issues and assuage their
concerns. Representing an incremental decision to
adopt, the MOH agreed to continue service delivery
in the pilot districts without interruption and to re-
vise the National Health Policy to allow provision of
DMPA by CBD agents. All present at the meeting
endorsed the Road Map for National Scale-Up. Soon
after, government leadership changed, necessitating
renewed advocacy targeting new MOH staff. Involv-
ing a highly respected and influential policy level
champion as a knowledge broker throughout the
translation phase supported the engagement of key
government decision-makers, built their trust in the
interpersonal and organisational processes, and en-
hanced the communication between all the key ac-
tors. The champion was a Zambian obstetrician and
gynaecologist with extensive experience in FP and
maternal health programmes at both the country and
global level. He was familiar with FHI 360’s global
work in expanding community-based access to inject-
ables through community health workers, was a
strong supporter of the practice, and felt passionate
about advocating for policy-level changes in Zambia.
Initial expansion within the pilot study districts and
one new district began in January 2012 and required
technical assistance to the MOH and the newly formed
Ministry of Community Development, Maternal and
Child Health to advance the policy change dialogue and
foster high-level ownership of the Road Map. By July
2012, the government pledged to increase contraceptive
prevalence through various strategies, including reducing
barriers to task sharing and doubling budget allocations
for FP, an important step toward institutionalisation. In
September 2012, a delegation of Zambian stakeholders
participated in a study tour to observe Rwanda’s robust
CBFP programme and to engage with stakeholders
around important policy-level and operational issues.
Despite ongoing stakeholder engagement and advocacy
during this period, DMPA services stalled by June 2013
due to the lack of policy change and funds. However,
high-level endorsements, including from the First Lady
of Zambia, helped spur subsequent actions, including a
rapid assessment of the performance of CBD distribu-
tion of DMPA and development of a National CBD of
Injectables Strategy. Additional technical assistance was
provided in the development of the guidelines, training
curriculum and programme implementation tools based
on learning from the pilot project. On January 22, 2016,
the Zambia MOH gave official authorisation to scale-up
the use of CBDs in the provision of injectable contracep-
tives. With funding, tools and guidance in place, and
technical capacity within implementing organisations,
this decision reflects a substantive move into the institu-
tionalisation phase.
Future applications in the real world
Ensuring that evidence is understood and meaning-
fully applied to programmes and polices requires
intentional and systematic efforts. This simple, prag-
matic framework provides a roadmap for the variety
of inputs that are needed to undertake research with
the end in mind, ensuring that key actors are engaged
at various time points for the production and use of
relevant evidence in programmes and policies. We
have provided concrete examples of how RU activities
within the framework phases were applied, drawing
from a real-world case study of CBD of FP services
in Zambia, just one of many experiences from over a
decade of implementing global health research and
programmes that helped to shape the development of
this framework. In so doing, we aimed to add value
over existing RU frameworks. Specifically, we posit
that this framework:
Fig. 2 Timeline of research utilisation (RU) process for Zambia community-based access to depot-medroxyprogesterone acetate (DMPA)
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 is simple enough for use by many different
audiences, including end users of evidence;
 captures the fluid and dynamic RU process through
its circular representation and explicit
acknowledgement of feedback loops;
 is relevant for application in LMICs, having drawn from
our organisational expertise working in these contexts;
 builds upon other evidence-based RU frameworks;
 highlights the important roles of, and interplay
between, three categories of key actors, namely
evidence producers, knowledge brokers and end
users of evidence, all of whom must interact and
collaborate for the success of RU efforts;
 focuses attention on the required inputs, including time
and activities within the important translation phase;
 can be complimented by a suite of RU tools that we
have developed.
Like any framework, this one has its limitations. As we
have already noted, it is impossible to develop a frame-
work that will fit every practitioner’s needs, particularly
for such a dynamic and complicated process as RU. We
opted to keep this framework simple and, in so doing,
may not have represented all of the complex systems in
which global health and development programmes must
work. Nonetheless, it draws upon and reflects a thor-
ough examination of the complex dynamics involved in
achieving research utilisation. There may be additional
expenses for implementing RU strategies and applying
the framework, such as use of knowledge brokers, which
are unavailable in non-grant funded situations. Further-
more, many external factors that may dictate the success
or failure of research and evidence uptake, such as cap-
acity or political climate, are not visually captured.
Like any process, it is important to evaluate whether
the RU efforts actually result in increased uptake. Our
framework emphasises building on evidence-based inter-
ventions, dynamic feedback and iterative processes; how-
ever, there is no visual evaluation component in the
framework. While there is an increased recognition in
the knowledge translation world of the need for evalu-
ation of RU efforts, evaluation of these types of interven-
tions is complex and assessing the impact of research
uptake has often been limited to bibliometric methods
[46], small sample surveys of researchers and decision-
makers [47, 48], or qualitative methods to capture
perspectives [18]. A mapping study of the knowledge
mobilisation landscape in healthcare, social care and
education found that formal evaluation of RU activities
were rare [49]. Future research is needed on evaluation
techniques for RU activities, particularly to assess their
processes and impacts.
Application of this framework offers the potential to
improve policy and programmes by increasing the
likelihood that research results will be relevant, well-
documented, easily communicated and understood, scal-
able, and built upon existing systems. We hope that global
health and development stakeholders will apply it, docu-
ment its use, assess its utility and improve upon it. It is
not enough to just invest in research.
Endnotes
1FHI 360 is a non-profit human development organ-
isation dedicated to improving lives in lasting ways by
advancing integrated, locally driven solutions. FHI 360
serves more than 70 countries and all of the United
States and its territories. More information can be found
at: http://www.fhi360.org/
2A package of research utilisation strategic planning
tools are available at: https://www.fhi360.org/resource/
research-utilization-strategic-planning-tools
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